Drug launch strategy that clears adoption barriers before launch day.

Drug launch strategy is the plan that decides how a new medicine reaches prescribers, payers and patients in its first 12 months on the market. A drug launch plan sets which HCP and payer segments to win first, which adoption barriers to clear and where field effort and budget go before and after approval. Nextyn builds that plan from primary interviews and surveys with the prescribers, payers and patients a pharmaceutical drug launch depends on, so barriers surface before launch day.

A Nextyn drug launch readiness assessment covers three pre-launch activities: mapping adoption barriers by stakeholder, ranking priority HCP and payer segments, and building a launch action plan with a competitor watchlist. Each activity rests on primary interviews and surveys, not desk research:

• Adoption-barrier map: the clinical, access and practical hurdles each stakeholder group raises, ranked by their effect on uptake
• Segment ranking: the prescriber and payer segments most likely to adopt early
• Launch action plan: the actions to take before and after approval, with the competitor moves to watch

Nextyn interviews the five stakeholder groups that decide early uptake: prescribing physicians, key opinion leaders, payers, hospital formulary decision-makers, and patients and caregivers. Each launch assessment draws its sample from these groups, matched to the therapy area and the launch markets:

• Prescribing HCPs, by specialty and practice setting
• Key opinion leaders who shape treatment guidelines
• Payers, health-plan and HTA decision-makers
• Hospital pharmacy and formulary committee members
• Patients and caregivers, where the treatment pathway depends on them

Nextyn runs drug launch research in the United States, Canada, the United Kingdom, Germany, France, Italy and Spain, among other markets. Markets are agreed at scoping and follow the launch sequence, so a US-first launch and an EU4-plus-UK launch are each researched in the order they go live. Recent Nextyn pharma work includes payer and hospital research for a cardiovascular launch in the UK, patient-pathway research for a rare disease in Germany, France and Italy, and indication prioritization in Spain.

Nextyn recommends starting drug launch planning research before the pivotal Phase III readout, while pricing, positioning and field-force plans are still open. At that stage a barrier costs least to remove: messages can be rewritten, evidence gaps closed and segment priorities set before launch budgets are committed. Research that starts after approval still sharpens the first 12 months, but that research adjusts a plan already in motion instead of shaping it.

A Nextyn drug launch strategy project runs in four steps, from brief to read-out, and nothing is commissioned until the client approves the plan. The client sees the sample, method and price before any fieldwork, and reads every interview with the Nextyn team at the end.

1. Submit the brief: the therapy, the launch markets and the decision the research must settle.
2. Receive a plan within 48 hours: who Nextyn will interview, how, and what the work costs.
3. Approve the plan: fieldwork starts only after sign-off.
4. Review the read-out: every interview read together, showing where stakeholders agree, where they conflict and what is still open.

Nextyn sends a research plan within 48 hours of receiving the brief, stating who will be interviewed, how, and what the work costs. The plan sets the fieldwork length for the markets and stakeholder groups in scope, so a single-market payer and prescriber study and a five-country launch read each get their own drug launch research timeline. Nothing is commissioned until the plan is approved.

Nextyn's drug launch research answers one therapy's launch questions with new evidence from that therapy's own prescribers and payers, while a syndicated report describes a whole market for every subscriber. The two answer different questions: the report sizes the market, and the research shows what will move it for one launch.